scholarly journals Impact of COVID-19 in early breast cancer management: a summary of the current evidence

2021 ◽  
Author(s):  
Francisco Pimentel Cavalcante ◽  
Edson Abdala ◽  
Leonardo Weissmann ◽  
Carlos Eduardo dos Santos Ferreira ◽  
Gilberto Amorim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Expert Panel ◽  
Relevant Information ◽  
Current Evidence ◽  
Breast Cancer Patients ◽  
Essential Information ◽  
Cancer Management ◽  
Breast Cancer Management ◽  
The Impact

Purpose: An Expert Panel on Breast Cancer and COVID-19 was convened to address the impact of the COVID-19 pandemic for early breast cancer management. Methods: In order to ensure the most clinically relevant information was addressed, essential information was drawn from several of the latest national and international guidelines and another technical document. The Expert Panel met in five virtual closed sessions from November 2020 to May 2021 to consult on the relevant data from evidence-based results. The data gathered were discussed on an online platform (Within3 ®). Results: This paper reports the Expert Panel’s highlights of these meetings’ discussions. In addition, it provides practical recommendations covering topics regarding diagnosis, treatment, and management of breast cancer patients in clinical settings routinely encountered by HCPs amid the COVID-19 pandemic. Conclusions: It was provided guidance on several topics regarding eBC management amid the COVID-19 pandemics to inform safer care practices.

Getting It Wrong Most of The Time: Comparing Trialists’ Choice of Primary Outcome With What Patients And Health Professionals Want

2021 ◽  
Author(s):  
Shaun Treweek ◽  
Viviane Miyakoda ◽  
Dylan Burke ◽  
Frances Shiely
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Health Care Professionals ◽  
Primary Outcome ◽  
Healthcare Professionals ◽  
Breast Cancer Patients ◽  
Additional Information ◽  
Cancer Management ◽  
Breast Cancer Management ◽  
Secondary Outcomes

Abstract Background: Randomised trials support improved decision-making through the data they collect. One important piece of data is the primary outcome – so called because it is what the investigators decide is the most important. Secondary outcomes provide additional information to support decision-making. We were interested in knowing how important patients and healthcare professionals consider the outcomes (especially the primary outcome) measured in a selection of published trials. Methods: The work had three stages: 1. We identified a body of late-stage trials in two clinical areas, breast cancer management and nephrology. 2. We identified the primary and secondary outcomes for these trials. 3. We randomly ordered these outcomes and presented them to patients and healthcare professionals (with experience of the clinical area), and we asked them to rank the importance of the outcomes. They were not told which outcomes trial authors considered primary and secondary. Results: In our sample of 44 trials with 46 primary outcomes, 29 patients, one patient representative and 12 healthcare professionals together ranked the primary outcome as the most important outcome 13/46 times, or 30%. Breast cancer patients and health care professionals considered the primary outcome to be the most important outcome for 8/21 primary outcomes chosen by trialists. For nephrology, the equivalent figure was 5/25. The primary outcome appeared in a respondent’s top 5 ranked outcomes 151/178 (85%) times for breast cancer and 225/259 (87%) times for nephrology even if the primary wasn’t considered the most important outcome. Conclusions: The primary outcome in a trial is the most important piece of data collected. It is used to determine how many participants are required, and it is the main piece of information used to judge whether the intervention is effective or not. Our study found that in the view of patients and healthcare professionals, teams doing trials in breast cancer management and nephrology got their choice of primary outcome wrong 70% of the time.

Suggested modifications in the management of breast cancer patients in the era of COVID-19 pandemic: a web-based survey. (Preprint)

2021 ◽  
Author(s):  
Shereef Elsamany ◽  
Mohamed Elbaiomy ◽  
Ahmed Zeeneldin ◽  
Emad Tashkandi ◽  
Fayza Hassanin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
United Arab Emirates ◽  
Hormonal Therapy ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Web Based ◽  
Cancer Management ◽  
Breast Cancer Management ◽  
Positive Breast Cancer

BACKGROUND Management of cancer patients in the current era of COVID-19 pandemic poses a significant challenge on health care systems. OBJECTIVE We explored the views of oncologists for the management of breast cancer patients during COVID-19 pandemic. METHODS A web-based questionnaire using SurveyMonkey was submitted to licensed oncologists involved in breast cancer management in Saudi Arabia, Egypt and United Arab Emirates. The survey focused on characteristics of participants, infection risk among cancer patients and possible treatment modifications related to different types of breast cancer RESULTS The survey was completed by 82 participants. For early HR positive, HER2-negative breast cancer,74.4% supported using neoadjuvant hormonal therapy in selected patients, and 58.0% preferred giving 6 over 8 cycles of adjuvant chemotherapy when indicated. Only 42.7% preferred CDK4/6 inhibitor with hormonal therapy as first line in all patients with metastatic HR-positive disease. 67.1% of participants supported using adjuvant trastuzumab for 6 instead of 12 months in selected patients with HER2-positive breast cancer. For metastatic HER2-positive, HR-positive breast cancer, 80.5% of participants supported the use of hormonal therapy with dual anti-HER2 blockade in selected patients. The preferred choice of 1st line treatment in metastatic triple negative patients with BRCA mutation and PDL1<1%, was PARP inhibitor according to 42.5% of the participants, and atezolizumab with nabpaclitaxel if the PDL1>1% according to 70.4% of the participants. CONCLUSIONS Several modifications in breast cancer management is supported by the survey participants. These modifications need to be discussed on local basis taking into account the local infrastructure and available resources. CLINICALTRIAL none

scholarly journals Breast-Conserving Therapy Versus Modified Radical Mastectomy in the Early Breast Cancer Management: Oncological Outcome and Quality of Life

2019 ◽  
Vol 87 (June) ◽  
pp. 1639-1647
Author(s):  
HALA A. EL-MAGHAWRY, M.D. MOHAMED F. AMIN, M.D. ◽  
MOSTAFA M. KHAIRY, M.D. AHMED S. ARAFA, M.D. ◽  
HANAA A. NOFAL, M.D. ABD EL-MOTALEB MOHAMED, M.D. ◽  
AHMED EL-AZONY, M.D.
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Early Breast Cancer ◽  
Radical Mastectomy ◽  
Oncological Outcome ◽  
Breast Conserving Therapy ◽  
Modified Radical Mastectomy ◽  
Cancer Management ◽  
Breast Cancer Management

scholarly journals Upper limb lymphedema related to breast cancer therapy: incidence, risk factors, diagnostic techniques, risk reduction and optimal management

2018 ◽  
Vol 5 (11) ◽  
pp. 3633
Author(s):  
Hatem A. Saleh ◽  
Tarek M. Rageh ◽  
Suzan A. Alhassanin ◽  
Mohamed A. Megahed
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cancer Patients ◽  
Upper Limb ◽  
Diagnostic Techniques ◽  
Breast Cancer Patients ◽  
Breast Cancer Therapy ◽  
Cancer Management ◽  
Breast Cancer Management ◽  
Incidence Risk

Background: Lymphedema remains to be a great source of morbidity for breast cancer survivors. The aim of this work is to study upper limb lymphedema following breast cancer therapy for breast cancer patients regarding its incidence, risk factors, diagnostic techniques, risk reduction and optimal management.Methods: This prospective study was done on two hundred breast cancer patients who underwent breast cancer management. The study was done in the period between May 2016 and July 2018. Exclusion criteria were Male patients, Female patients with metastatic breast cancer and who already had upper limb lymphedema before breast cancer management. All patients underwent follow up for incidence, risk factors, diagnostic techniques and management of lymphedema. Statistical analysis used: The collected data were organized, tabulated and statistically analyzed using SPSS softwareResults: The incidence of lymphedema was (18 %) distributed as follow: grade I = 55.6%, grade II = 33.3%, grade III = 11.1 % and grade IV = 0 %. The most relevant risk factors for development of lymphedema were: age between 41 and 50 years and diabetes mellitus. Higher incidence of pain (66.7%) and restricted motion (61.1%) were observed in lymphedema cases.Conclusions: Old (41:50 years) and diabetic patients are at the highest risk for developing lymphedema. Breast cancer patients of stage IIIB who had undergone modified radical mastectomy or who developed postoperative seroma are at higher risk for developing lymphedema. Physical exercises and compression garment are important part of treatment plan.

scholarly journals The impact of COVID-19 on and recommendations for breast cancer care: the Singapore experience

2020 ◽  
Vol 27 (9) ◽  
pp. R307-R327 ◽  
Author(s):  
Jack Junjie Chan ◽  
Yirong Sim ◽  
Samuel Guan Wei Ow ◽  
Joline Si Jing Lim ◽  
Grace Kusumawidjaja ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Evidence Base ◽  
Healthcare Sector ◽  
Public Healthcare ◽  
Global Public Health ◽  
Medical Systems ◽  
Outbreak Response ◽  
Cancer Management ◽  
Breast Cancer Management ◽  
The Impact

The ensuing COVID-19 pandemic poses unprecedented and daunting challenges to the routine delivery of oncological and supportive care to patients with breast cancer. Considerations include the infective risk of patients who are inherently immunosuppressed from their malignancy and therapies, long-term oncological outcomes from the treatment decisions undertaken during this extraordinary period, and diverted healthcare resources to support a coordinated whole-of-society outbreak response. In this review, we chronicle the repercussions of the COVID-19 outbreak on breast cancer management in Singapore and describe our approach to triaging and prioritising care of breast tumours. We further propose adaptations to established clinical processes and practices across the different specialties involved in breast oncology, with references to the relevant evidence base or expert consensus guidelines. These recommendations have been developed within the unique context of Singapore’s public healthcare sector. They can serve as a resource to guide breast cancer management for future contingencies in this city-state, while certain elements therein may be extrapolatable to other medical systems during this global public health emergency.

scholarly journals Breast Medical Oncology in the Era of COVID-19 Pandemic

2020 ◽  
Vol 5 (S1) ◽  
pp. 187-190
Author(s):  
Rania Chacha ◽  
Said Afqir
Keyword(s):  
Breast Cancer ◽  
World Health ◽  
Breast Cancer Patients ◽  
Negative Effects ◽  
Infected People ◽  
Cancer Management ◽  
Breast Cancer Management ◽  
Life Threatening ◽  
Working Groups ◽  
Health Organization

The coronavirus disease 2019 (COVID-19) has spread over the majority of countries and it was declared as a pandemic on March 11th, 2020 by The World Health Organization. The number of infected people worldwide is still in progress. Patients diagnosed with cancer are a fragile population because of their chronic disease and related treatments, and therefore, requiring a particular management. Several international initiatives from scientific societies and working groups have provided updated guidance to improve the medical treatments of breast cancer. These recommendations aimed to mitigate the negative effects of this outbreak on prevention, diagnosis, and treatments. Notably, this should be used for prioritizing the various aspects of cancer care particularly breast cancer patients’ safety. In this editorial, we shortly review the current guidelines for breast cancer management during this pandemic and illustrate the available treatments that should be prioritized. We believe this paper will be useful for young oncologists and physicians dealing with this emerging life-threatening disease.

scholarly journals Correlating imaging parameters with molecular data: An integrated approach to improve the management of breast cancer patients

2020 ◽  
Vol 35 (1_suppl) ◽  
pp. 47-50 ◽  
Author(s):  
Mariarosaria Incoronato ◽  
Peppino Mirabelli ◽  
Anna Maria Grimaldi ◽  
Andrea Soricelli ◽  
Marco Salvatore
Keyword(s):  
Breast Cancer ◽  
Integrated Approach ◽  
Molecular Data ◽  
Cancer Tissue ◽  
Breast Cancer Patients ◽  
Cancer Management ◽  
Imaging Parameters ◽  
Diagnosis And Prognosis ◽  
Breast Cancer Management ◽  
Genetic Level

The goal of this review is to provide an overview of the studies aimed at integrating imaging parameters with molecular biomarkers for improving breast cancer patient’s diagnosis and prognosis. The use of diagnostic imaging to extract quantitative parameters related to the morphology, metabolism, and functionality of tumors, as well as their correlation with cancer tissue biomarkers is an emerging research topic. Thanks to the development of imaging biobanks and the technological tools required for extraction of imaging parameters including radiomic features, it is possible to integrate imaging markers with genetic data. This new field of study represents the evolution of radiology–pathology correlation from an anatomic–histologic level to a genetic level, which paves new interesting perspectives for breast cancer management.

Sign in / Sign up

Export Citation Format

Share Document